Vimarsana
Biggest News Aggregation in the World

Page 21 - Cellular Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cellular Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cellular Therapy Today - Breaking & Trending Today

Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors - Vimarsana News

Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors

/PRNewswire/ -- Deka Biosciences ("Deka") today announced the appointments of Stanley Frankel, M.D., FACP, as senior clinical advisor, interim chief medical...

Amrita Hospital, Faridabad, Introduces CAR T-cell Therapy for Patients with Blood Cancers - Vimarsana News

Amrita Hospital, Faridabad, Introduces CAR T-cell Therapy for Patients with Blood Cancers

 FARIDABAD: Amrita Hospital in Faridabad has introduced CAR T-cell (Chimeric antigen receptor) therapy for certain cancer patients, which is considered a significant breakthrough in B cell lymphoma and leukemia treatment, with promising results

ASTCT Response to FDA Approval of Gene Therapies for Treatment of Sickle ... - Vimarsana News

ASTCT Response to FDA Approval of Gene Therapies for Treatment of Sickle ...

ASTCT Response to FDA Approval of Gene Therapies for Treatment of Sickle ...

New sickle cell treatment has roots at Children's Hospital of Philadelphia - Vimarsana News

New sickle cell treatment has roots at Children's Hospital of Philadelphia

CHOP pioneered a gene therapy that's already helping patients who have sickle cell disease, an inherited blood disorder.

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease - Vimarsana News

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, for the treatment of sickle cell disease (SCD) in patients ...